Aegros

Hyperimmunes

Passive immunity for frontline healthcare workers

What makes us special

The COVID-19 pandemic has fundamentally and irrevocably changed the world. 

At the time of writing, there have been over 60 million cases worldwide, and more than 1.5 million people have died. Every country is being impacted, and the end is not yet in sight – a vaccine is not estimated to be available until at least 2021. 

So, how do we treat patients and keep frontline healthcare workers safe?

At Aegros, we are working on an answer.

We are developing a COVID-19 hyperimmune therapy that may potentially give frontline healthcare workers passive immunity to the virus.

How does it work?

When people contract COVID-19, their immune systems enter a state of hyperactivity to combat the illness. People who recovered from COVID-19 have antibodies to the virus and it is these COVID-19-fighting antibodies Aegros is using to supply passive immunity – temporary protection from the virus – for frontline healthcare workers.

There is significant scientific research backing this approach including the Mayo Clinic and Johns Hopkins University. Aegros will be testing this via its clinical trial which has ethnics approval.

We have acquired a 4,500m2 TGA-approved facility in Sydney which we are upgrading specifically for plasma fractionation. 

Should this trials prove successful, our HaemaFrac™,  our HaemaFrac™ technology and hyperimmune product will be used to treat COVID-19 patients and provide passive immunity to frontline healthcare workers both in Australia and around the world. 

The opportunity for Aegros is clear, given every single economy in the world is being severely impacted by the virus. Current fractionation techniques are costly and inefficient in a world with a global plasma shortage. 

Aegros has the advantage of being a small and agile biotech.

The even better news? Once the pandemic is over, our technology can create hyperimmune products for a wide range of diseases and illnesses, from rabies to Middle Eastern Respiratory Virus (MERS).

We are supremely confident in our HaemaFrac™ technology.